| |
 | | | |
|
|
|
DRUG AND ALCOHOL DEPENDENCE
| |
| | |
|
|
An International Journal on Biomedical and Psychosocial Approaches
Sponsored by the  College on Problems of Drug Dependence
Content Areas for Associate Editors Drug and Alcohol Dependence
DRUG AND ALCOHOL DEPENDENCE CONTENT AREAS FOR EACH ASSOCIATE EDITOR
August, 29, 2011
Behavioural Pharmacology (Craig Rush)
Laboratory-based studies of animal and human behavioral pharmacology, clinical pharmacology, medications development, conditioning, expectancies, impulsivity, social and economic behavior, and abuse liability assessment. Also included would be laboratory-based assessment of the effects of substance use, including research in neuropsychology and cognitive psychology. Neuro-imaging studies in humans would also likely be included as well.
Comorbidity, Psychiatric Epidemiology, Etiology, Nosology and Genetics (Deborah Hasin)
Epidemiologic studies of the incidence, prevalence, and persistence of substance abuse in cross-national, national, community, clinical and other specific populations. Studies of time trends in substance use, substance use disorders or related health and psychosocial consequences of substance use. Studies of contextual factors defined by place, time (period/cohort) or group exposure to particular experiences. Inter-generational transmission studies. Studies of psychiatric comorbidity, cognitive functioning, personality, and attitudes/expectancies. Studies explaining gender or ethnic differences and/or disparities. Genetic or gene x environment association studies. Psychosocial and pharmacological interventions to reduce substance use and substance use disorders or improve related behaviors (e.g., poor antiretroviral adherence)in drug treatment and other health settings including primary care. Treatment development, clinical trials, treatment patient matching, cost-effectiveness, and treatment access. Assessment, diagnosis and nosology, including DSM-5 issues, latent variable analyses and instrument development and testing.
Etiology, Epidemiology, Prevention &Policy (Steffanie Strathdee)
Clinical and both small population-based studies of genetic, psychosocial and contextual risk factors, comorbidity, individual differences, personality, stress, aggression and violence, family, attitudes and expectancies, developmental periods, assessment, ethnic and gender issues. This area could also include same aspects of the consequences of substance use disorders, including effects of perinatal exposure, psychosocial effects, and developmental effects. Population genetics research would also fit. This content also area includes larger population-based studies of incidence and prevalence, both on general and special populations, of substance use disorders as well as related conditions such as HIV/AIDS, high risk behaviors and comorbidities. Included would be studies of student and other adolescent substance use, cross-cultural research, ethnography, survey development, trajectories, and multivariate research methods development. Prevention research, including prevention trials and services research relating to the dissemination of evidence-based prevention. In addition, history, law, anthropology, economics, sociology and policy studies would be included here.
Etiology, Treatment and Human Genetics (Wim van den Brink)
Clinical and population-based studies of genetic, psychosocial and contextual risk factors for the development and persistence of substance use disorders and other addictive behaviors, including individual differences, personality, stress, aggression and violence, family, attitudes and expectancies, developmental periods, ethnic and gender issues. Included would be studies of student and other adolescent substance use, cross-cultural research and research on psychiatric comorbity.
Treatment and services research, including pharmacotherapies and psychosocial interventions, clinical trials, patient-treatment matching (including pharmacogenomics), cost-effectiveness, treatment access, outcomes research, quality of life assessments, and methodology related to treatment and services research. Assessment, diagnosis and nosology are also included. This editor may also cover studies of the biomedical and behavioral representations and consequences of substance abuse, including neurocognitive testing and neuroimaging.
Human Psychopharmacology and Genetics (Marcus Munafò)
Human laboratory studies of the effects of substance use and pharmacotherapies on measures of cognitive and emotional processing, including neuroimaging studies. Human research related to alcohol and tobacco, and medications development. Genetic epidemiological studies of substance use phenotypes, including candidate gene and genomewide methods, gene x environment interaction studies, and imaging genetic studies.
Neuropsychopharmacology and Treatment (Lin Lu)
Laboratory-based studies of animal and human in molecular, cellular, systems, cognitive and behavioural level to understand the neuronal processes underlying drug addiction and related diseases are focused. Treatment targets addicted brain from gene therapy to behavioural therapy, including medication discovery, treatment development, clinical trials, cost-effectiveness, and methodology. It is particularly focused on neurobiological mechanism and clinical treatment for drug relapse after long-term abstinence.
Preclinical and Clinical Neurosciences (Linda Porrino)
Studies using modern neuroscience methods including neurobiology, molecular biology, molecular genetics, proteomics, and neuroimaging are covered. Both preclinical and clinical (animal and human) neuroscience studies are included, particularly those involving imaging. This content area also includes some synthetic chemistry, biological and physical chemistry, in vitro and in vivo pharmacology and toxicology, and immunology.
Services and Prevention, Technology Transfer, and Treatment (Jan Copeland)
Jan Copeland is a Professor in the Faculty of Medicine at the University of New South Wales. She is Director of the National Cannabis Prevention and Information Centre (NCPIC) and an Assistant Director of the National Drug and Alcohol Research Centre at that University. Her academic salary is provided by the Australian Government's Department of Health and Ageing as the NCPIC funder. She is a past recipient of a NIDA research grant, grants from the Australian National Health and Medical Research Council, the NSW Health Department, ZonMW and the Australian Rotary Health Fund. Each year she typically receives honoraria to attend conferences or provide training. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Copeland for her efforts as an Assistant Editor of the journal. Dr Copeland has never received any funds from pharmaceutical companies but is involved in a clinical trial of a medication that is being provided free of charge by the manufacturer. Professor Copeland has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as Assistant Editor aside from possible inclusion in superannuation funds over which she has no control as an individual investor.
Treatment and Services (Kyle Kampman)
Most treatment and services research, including both pharmacotherapies and psychosocial interventions, treatment development, clinical trials, treatment patient matching, perinatal addictions, cost-effectiveness, treatment access, outcomes research and methodology related to treatment and services research. It would also include those aspects of diagnosis and nosology that are pertinent to assessment and treatment, such as scale development and validation. Research on knowledge transfer and dissemination of treatment are also pertinent here. Research on biomarkers (including analytical chemistry, urinalysis and related monitoring) as they relate to treatment outcomes would be included as well.
|
|
| |
| | |
|
|
| |
|
|
